AQP4 and myeloid sarcoma: For the misclassification study, 1748 patients from the CGRD cohort were initially diagnosed with MS, of whom 104 patients were ultimately reclassified as having NMOSD with a positive status on anti-AQP4 autoantibody testing (Fig. 1A).